234 related articles for article (PubMed ID: 27635623)
1. Stereotactic Ablative Radiotherapy (SABR) for Large Renal Tumors: A Retrospective Case Series Evaluating Clinical Outcomes, Toxicity, and Technical Considerations.
Correa RJM; Rodrigues GB; Chen H; Warner A; Ahmad B; Louie AV
Am J Clin Oncol; 2018 Jun; 41(6):568-575. PubMed ID: 27635623
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Stereotactic Ablative Radiation Therapy for Renal Cell Carcinoma Extracranial Metastases.
Wang CJ; Christie A; Lin MH; Jung M; Weix D; Huelsmann L; Kuhn K; Meyer J; Desai N; Kim DWN; Pedrosa I; Margulis V; Cadeddu J; Sagalowsky A; Gahan J; Laine A; Xie XJ; Choy H; Brugarolas J; Timmerman R; Hannan R
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):91-100. PubMed ID: 28587057
[TBL] [Abstract][Full Text] [Related]
3. The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis.
Correa RJM; Louie AV; Zaorsky NG; Lehrer EJ; Ellis R; Ponsky L; Kaplan I; Mahadevan A; Chu W; Swaminath A; Hannan R; Onishi H; Teh BS; Muacevic A; Lo SS; Staehler M; Siva S
Eur Urol Focus; 2019 Nov; 5(6):958-969. PubMed ID: 31248849
[TBL] [Abstract][Full Text] [Related]
4. A prospective phase I dose-escalation trial of stereotactic ablative radiotherapy (SABR) as an alternative to cytoreductive nephrectomy for inoperable patients with metastatic renal cell carcinoma.
Correa RJM; Ahmad B; Warner A; Johnson C; MacKenzie MJ; Pautler SE; Bauman GS; Rodrigues GB; Louie AV
Radiat Oncol; 2018 Mar; 13(1):47. PubMed ID: 29558966
[TBL] [Abstract][Full Text] [Related]
5. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Louie AV; Warner A; Muacevic A; Gandhidasan S; Ponsky L; Ellis R; Kaplan I; Mahadevan A; Chu W; Swaminath A; Onishi H; Teh B; Correa RJ; Lo SS; Staehler M
Cancer; 2018 Mar; 124(5):934-942. PubMed ID: 29266183
[TBL] [Abstract][Full Text] [Related]
6. Stereotactic Ablative Radiation Therapy (SAbR) Used to Defer Systemic Therapy in Oligometastatic Renal Cell Cancer.
Zhang Y; Schoenhals J; Christie A; Mohamad O; Wang C; Bowman I; Singla N; Hammers H; Courtney K; Bagrodia A; Margulis V; Desai N; Garant A; Choy H; Timmerman R; Brugarolas J; Hannan R
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):367-375. PubMed ID: 31377159
[TBL] [Abstract][Full Text] [Related]
7. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function.
Senger C; Conti A; Kluge A; Pasemann D; Kufeld M; Acker G; Lukas M; Grün A; Kalinauskaite G; Budach V; Waiser J; Stromberger C
BMC Urol; 2019 Oct; 19(1):96. PubMed ID: 31638979
[TBL] [Abstract][Full Text] [Related]
8. Oligo metastatic renal cell carcinoma: stereotactic body radiation therapy, if, when and how?
Marvaso G; Corrao G; Oneta O; Pepa M; Zaffaroni M; Corso F; Gandini S; Cecconi A; Zerini D; Mazzola GC; Augugliaro M; Cossu Rocca M; Verri E; Cattani F; La Fauci F; Bergamaschi L; Luzzago S; Mistretta AF; Musi G; Nolè F; De Cobelli O; Orecchia R; Jereczek-Fossa BA
Clin Transl Oncol; 2021 Aug; 23(8):1717-1726. PubMed ID: 33687659
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic Ablative Radiation Therapy for Large (≥5 cm) Non-small Cell Lung Carcinoma.
McDermott RL; Mihai A; Dunne M; Keys M; O'Sullivan S; Thirion P; ElBeltagi N; Armstrong JG
Clin Oncol (R Coll Radiol); 2021 May; 33(5):292-299. PubMed ID: 33309479
[TBL] [Abstract][Full Text] [Related]
10. 5-year outcomes after stereotactic ablative body radiotherapy for primary renal cell carcinoma: an individual patient data meta-analysis from IROCK (the International Radiosurgery Consortium of the Kidney).
Siva S; Ali M; Correa RJM; Muacevic A; Ponsky L; Ellis RJ; Lo SS; Onishi H; Swaminath A; McLaughlin M; Morgan SC; Cury FL; Teh BS; Mahadevan A; Kaplan ID; Chu W; Grubb W; Hannan R; Staehler M; Warner A; Louie AV
Lancet Oncol; 2022 Dec; 23(12):1508-1516. PubMed ID: 36400098
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial.
Siva S; Bressel M; Sidhom M; Sridharan S; Vanneste BGL; Davey R; Montgomery R; Ruben J; Foroudi F; Higgs B; Lin C; Raman A; Hardcastle N; Hofman MS; De Abreu Lourenco R; Shaw M; Mancuso P; Moon D; Wong LM; Lawrentschuk N; Wood S; Brook NR; Kron T; Martin J; Pryor D;
Lancet Oncol; 2024 Mar; 25(3):308-316. PubMed ID: 38423047
[TBL] [Abstract][Full Text] [Related]
12. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial.
Siva S; Pham D; Kron T; Bressel M; Lam J; Tan TH; Chesson B; Shaw M; Chander S; Gill S; Brook NR; Lawrentschuk N; Murphy DG; Foroudi F
BJU Int; 2017 Nov; 120(5):623-630. PubMed ID: 28188682
[TBL] [Abstract][Full Text] [Related]
13. Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report From the International Radiosurgery Oncology Consortium for Kidney (IROCK).
Siva S; Correa RJM; Warner A; Staehler M; Ellis RJ; Ponsky L; Kaplan ID; Mahadevan A; Chu W; Gandhidasan S; Swaminath A; Onishi H; Teh BS; Lo SS; Muacevic A; Louie AV
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):941-949. PubMed ID: 32562838
[TBL] [Abstract][Full Text] [Related]
14. Stereotactic radiosurgery for intraventricular brain metastases.
Farnia B; Voong KR; Brown PD; Allen PK; Guha-Thakurta N; Prabhu SS; Rao G; Wang Q; Zhao Z; Mahajan A
J Neurosurg; 2014 Dec; 121 Suppl():26-34. PubMed ID: 25434934
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma.
Siva S; Pham D; Gill S; Corcoran NM; Foroudi F
BJU Int; 2012 Dec; 110(11 Pt B):E737-43. PubMed ID: 23107102
[TBL] [Abstract][Full Text] [Related]
16. Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.
Mesko S; Sandler K; Cohen J; Konecny G; Steinberg M; Kamrava M
Int J Gynecol Cancer; 2017 Feb; 27(2):403-408. PubMed ID: 27870704
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma.
Ponsky L; Lo SS; Zhang Y; Schluchter M; Liu Y; Patel R; Abouassaly R; Welford S; Gulani V; Haaga JR; Machtay M; Ellis RJ
Radiother Oncol; 2015 Oct; 117(1):183-7. PubMed ID: 26362723
[TBL] [Abstract][Full Text] [Related]
18. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II.
Siva S; Chesson B; Bressel M; Pryor D; Higgs B; Reynolds HM; Hardcastle N; Montgomery R; Vanneste B; Khoo V; Ruben J; Lau E; Hofman MS; De Abreu Lourenco R; Sridharan S; Brook NR; Martin J; Lawrentschuk N; Kron T; Foroudi F
BMC Cancer; 2018 Oct; 18(1):1030. PubMed ID: 30352550
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic Ablative Body Radiotherapy for Primary Renal Cell Carcinoma in Non-surgical Candidates: Initial Clinical Experience.
Chang JH; Cheung P; Erler D; Sonier M; Korol R; Chu W
Clin Oncol (R Coll Radiol); 2016 Sep; 28(9):e109-14. PubMed ID: 27131756
[TBL] [Abstract][Full Text] [Related]
20. Phase 2 Trial of Stereotactic Ablative Radiotherapy for Patients with Primary Renal Cancer.
Hannan R; McLaughlin MF; Pop LM; Pedrosa I; Kapur P; Garant A; Ahn C; Christie A; Zhu J; Wang T; Robles L; Durakoglugil D; Woldu S; Margulis V; Gahan J; Brugarolas J; Timmerman R; Cadeddu J
Eur Urol; 2023 Sep; 84(3):275-286. PubMed ID: 36898872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
